{"id":"W4319068412","doi":"10.1200/jco.22.01990","title":"Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":512,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Carboplatin; Internal medicine; Hazard ratio; Lung cancer; Placebo; Chemotherapy; Oncology; Population; Clinical trial; Phases of clinical research; Cancer; Surgery; Confidence interval; Pathology; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04580318,0.0009835492,0.003067029,0.0007740175,0.0006538806,0.003266167,0.001853965,0.00209228,0.002538192],"category_scores_gemma":[0.01756037,0.0006362746,0.003190318,0.001609658,0.0005194041,0.001912963,0.0009656092,0.005431406,0.001298139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00147539,"about_ca_system_score_gemma":0.003528483,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009503519,"about_ca_topic_score_gemma":0.00228039,"domain_scores_codex":[0.991508,0.005317071,0.0007580641,0.0002989133,0.001726463,0.000391325],"domain_scores_gemma":[0.9864172,0.004036872,0.002780213,0.001255959,0.003915463,0.001594352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1789837,0.006308082,0.01368265,0.01555873,0.008337022,0.0003573051,0.0005305702,0.002917021,0.01491476,0.003657706,0.1675456,0.5872069],"study_design_scores_gemma":[0.2187089,0.1114849,0.06012731,0.008602276,0.01448099,0.001346958,0.00027066,0.003924124,0.009255843,0.003251679,0.5682513,0.0002949207],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.3231155,0.4497939,0.03051646,0.03429607,0.01300128,0.03538539,0.05255381,0.002126778,0.05921078],"genre_scores_gemma":[0.5580463,0.1913348,0.05005429,0.0529086,0.006594288,0.04974495,0.07692507,0.00104489,0.0133469],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.04580318,"threshold_uncertainty_score":0.2422332,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06809060181907818,"score_gpt":0.4589729620350002,"score_spread":0.390882360215922,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}